News

Here’s what you missed this week on Managed Healthcare Executive.

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

This new generic medicine is designed to be a simple, once-daily treatment for children as young as three months old who weigh at least 13 pounds.

Wendy Watson takes over Kaiser Foundation Health Plan and Hospitals of the Northwest, and Corwin N. Harper becomes president of Kaiser Foundation Health Plan of Georgia.

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.

TriVerity focuses on whether the patient has an infection and how severely ill they are likely to become.

Ways workplaces and insurance companies have begun to support menopausal women, according to Jenifer Allbright, Director of G&A Beneficial at G&A Partners.

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22, 2025.

First discovered in the Netherlands roughly 24 years ago, HMPV belongs to the same viral family as RSV.

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it more difficult to be treated by traditional oral antidepressants.

The development of avian influenza vaccines is the main priority amid rising cases in the United States.

Health policy leaders say withdrawing from the WHO is a global health crisis in the making.

The president also promises to end the chronic disease epidemic and make two genders U.S. policy.

Datroway reduced disease progression by 37% when compared with chemotherapy.

Here’s what you missed this week on Managed Healthcare Executive.

A forecast of the year by Bill Kerr, M.D., MBA, CEO of Avalon Healthcare Solutions.

Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund, explains the biggest HIV issues anticipated this year.

Lenacapavir has the potential to transform HIV care and prevention, but only if access is broadened, according to Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund.

This ranking is based on the reviews of 12,372 consumers who evaluated their experiences with 16 major health insurance brands.

Michael Poku, M.D., chief clinical officer of Equality Health, shared his prediction for 2025.

But many existing models fall short of adhering to established best practices for economic evaluation, the review authors found. Another challenge: Existing models may not be well-suited for evaluating personalized treatments.

A prediction for 2025 from Laura Kohlhagen, M.D., MBA, chief medical officer, of Altera Digital Health.

Cancer mortality rates have decreased by 34% overall, but incidence rates for women of all ages continue to rise, according to a new report from the American Cancer Society.

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the intestinal tract, when compared to placebo.

Berge will serve in this role through the end of 2026, marking another milestone in her successful career in healthcare.

Luke Twelves, M.D., vice president of Medical for Lindus Health, shared his prediction for the year.

Lyle Berkowitz, M.D., CEO of KeyCare, gives a prediction for 2025.

A prediction for 2025 by George Pappas, CEO of Intraprise Health.

The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.

UnitedHealth Group reported a medical care ratio in 2024 of 85.5% compared with 83.2% in 2023.